IP Library Granted Patent US 10,406,363
Granted Patent B2
US 10,406,363 · App. 15/134,281 · Granted Sep 10, 2019

Evaluation of efficacy of epilepsy therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,406,363
App. No.
15/134,281
Granted
Sep 10, 2019
Kind
B2
Abstract

A method of detecting an improvement in a seizure condition of a patient includes identifying a first EEG synchronization of the seizure condition of the patient; applying a therapy configured to improve the seizure condition of the patient; and identifying a second EEG synchronization of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced EEG synchronization of the patient such that the second EEG synchronization is less than the first EEG synchronization.

Claims (70)

1. A method of detecting an improvement in a seizure condition of a patient, the method comprising:

identifying a first EEG synchronization of a first seizure of the patient;

applying a therapy configured to improve the seizure condition of the patient;

identifying a second EEG synchronization of a second seizure of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced EEG synchronization of the patient such that the second EEG synchronization is less than the first EEG synchronization; and

modifying the therapy based on at least one of the second EEG synchronization or a comparison of the first and second EEG synchronization.

2. The method of claim 1 , wherein the therapy is at least one of a vagus nerve stimulation therapy or a drug therapy.

3. The method of claim 1 , further comprising:

identifying a first amount of heart rate increase of the seizure condition of the patient;

identifying a second amount of heart rate increase of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced increase in heart rate of the patient wherein the second amount of heart rate increase is less than the first amount of heart rate increase.

4. The method of claim 1 , further comprising:

identifying a first duration of increased heart rate of the seizure condition of the patient;

identifying a second duration of increased heart rate of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced duration of increased heart rate wherein the second duration of increased heart rate is less than the first duration of increased heart rate.

5. The method of claim 1 , wherein the first and second EEG synchronization are determined for a plurality of EEG sensors and a plurality of frequency bands for each of the plurality of EEG sensors.

6. The method of claim 1 , wherein identifying the first EEG synchronization and identifying the second EEG synchronization each comprise:

extracting maximum wavelet coefficients in a plurality of epochs and a plurality of frequency bands for a plurality of EEG sensors;

computing a global spatial synchronization for each frequency band across the plurality of EEG sensors using the maximum wavelet coefficients; and

estimating a synchronizability index for each of the plurality of EEG sensors using the global spatial synchronization.

7. The method of claim 6 , further comprising, for each of the plurality of EEG sensors, classifying the EEG sensors as contributing to synchronization in response to determining a significance for each of the plurality of EEG sensors based on the synchronizability index, wherein the significance indicates an increase in the sychronizability index during the seizure.

8. The method of claim 7 , further comprising determining a number of EEG sensors contributing to seizure from the plurality of EEG sensors based on the significance for each of the plurality of EEG sensors.

9. The method of claim 8 , further comprising evaluating an efficacy of treatment by comparing the number of EEG sensors contributing to seizure in the first EEG synchronization to the number of EEG sensors contributing to seizure in the second EEG synchronization.

10. The method of claim 1 , further comprising providing a visual representation of at least one of the first EEG synchronization, the second EEG synchronization, or a comparison of the first and second EEG synchronization to at least one of the patient or a physician.

11. The method of claim 1 , further comprising generating an indication of an efficacy of the therapy using at least one of the second EEG synchronization or the comparison of the second EEG synchronization to the first EEG synchronization.

12. A device configured to detect an improvement in a seizure condition of a patient, the device comprising:

at least one EEG sensor configured to generate EEG data; and

a therapy analysis device configured to receive the EEG data,

wherein the therapy analysis device is configured to evaluate an effect of a therapy, the evaluation comprising:

identifying a first EEG synchronization of the seizure condition of the patient;

applying a therapy configured to improve the seizure condition of the patient;

identifying a second EEG synchronization of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced EEG synchronization of the patient such that the second EEG synchronization is less than the first EEG synchronization; and

modifying the therapy based on at least one of the second EEG synchronization or a comparison of the first and second EEG synchronization.

13. The device of claim 12 , wherein the therapy is at least one of a vagus nerve stimulation therapy or a drug therapy.

14. The device of claim 12 , further comprising at least one heart rate sensor.

15. The device of claim 14 , wherein the evaluation further comprises:

identifying a first amount of heart rate increase of the seizure condition of the patient;

identifying a second amount of heart rate increase of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced increase in heart rate of the patient wherein the second amount of heart rate increase is less than the first amount of heart rate increase.

16. The device of claim 14 , wherein the evaluation further comprises:

identifying a first duration of increased heart rate of the seizure condition of the patient;

identifying a second duration of increased heart rate of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced duration of increased heart rate wherein the second duration of increased heart rate is less than the first duration of increased heart rate.

17. The device of claim 12 , wherein the first and second EEG synchronization are determined for the at least one EEG sensor and a plurality of frequency bands for the at least one EEG sensor.

18. The device of claim 12 , wherein identifying the first EEG synchronization and identifying the second EEG synchronization each comprise:

extracting maximum wavelet coefficients in a plurality of epochs and a plurality of frequency bands for a plurality of EEG sensors;

computing a global spatial synchronization for each frequency band across the plurality of EEG sensors using the maximum wavelet coefficients; and

estimating a synchronizability index for each of the plurality of EEG sensors using the global spatial synchronization.

19. The device of claim 18 , wherein identifying the first EEG synchronization and identifying the second EEG synchronization each further comprises, for each of the plurality of EEG sensors, classifying the EEG sensors as contributing to synchronization in response to determining a significance for each of the plurality of EEG sensors based on the synchronizability index, wherein the significance indicates an increase in the sychronizability index during the seizure.

20. The device of claim 19 , wherein identifying the first EEG synchronization and identifying the second EEG synchronization each further comprises determining a number of EEG sensors contributing to seizure from the plurality of EEG sensors based on the significance for each of the plurality of EEG sensors.

21. The device of claim 20 , the therapy analysis device is further configured to evaluate the effect of a therapy by comparing the number of EEG sensors contributing to seizure in the first EEG synchronization to the number of EEG sensors contributing to seizure in the second EEG synchronization.

22. The device of claim 12 , the therapy analysis device is further configured to provide a visual representation of at least one of the first EEG synchronization, the second EEG synchronization, or a comparison of the first and second EEG synchronization to at least one of the patient or a physician.

23. The device of claim 12 , wherein the therapy analysis device is configured to generate an indication of an efficacy of the therapy using at least one of the second EEG synchronization or the comparison of the second EEG synchronization to the first EEG synchronization.

24. A method of detecting an improvement in a seizure condition of a patient, the method comprising:

identifying a first EEG synchronization of the seizure condition of the patient by:

extracting first maximum wavelet coefficients in a first plurality of epochs and a plurality of frequency bands for a plurality of EEG sensors;

computing a first global spatial synchronization for each frequency band across the plurality of EEG sensors using the first maximum wavelet coefficients; and

estimating a first synchronizability index for each of the plurality of EEG sensors using the first global spatial synchronization;

applying stimulation to a vagus nerve of the patient using a vagus nerve stimulation device configured to improve the seizure condition of the patient;

identifying a second EEG synchronization of the seizure condition of the patient subsequent to application of the stimulation by:

extracting second maximum wavelet coefficients in a second plurality of epochs and the plurality of frequency bands for the plurality of EEG sensors;

computing a second global spatial synchronization for each frequency band across the plurality of EEG sensors using the second maximum wavelet coefficients; and

estimating a second synchronizability index for each of the plurality of EEG sensors using the second global spatial synchronization; and

generating an indication of an efficacy of the stimulation to the vagus nerve using at least one of the second synchronizability index or a comparison of the second synchronizability index to the first synchronizability index.

25. The method of claim 24 , further comprising:

identifying a first amount of heart rate increase of the seizure condition of the patient;

identifying a second amount of heart rate increase of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced increase in heart rate of the patient wherein the second amount of heart rate increase is less than the first amount of heart rate increase.

26. The method of claim 24 , further comprising:

identifying a first duration of increased heart rate of the seizure condition of the patient;

identifying a second duration of increased heart rate of the seizure condition of the patient subsequent to application of the therapy, wherein an improvement of the seizure condition of the patient is demonstrated by a reduced duration of increased heart rate wherein the second duration of increased heart rate is less than the first duration of increased heart rate.

27. The method of claim 24 , further comprising for each of the plurality of EEG sensors, classifying the EEG sensors as contributing to synchronization in response to determining a first significance for each of the plurality of EEG sensors based on the first synchronizability index and determining a second significance for each of the plurality of EEG sensors based on the second synchronizability index, wherein the first and second significance indicate a statistically significant increase in the first and second sychronizability index, respectively, during the seizure.

28. The method of claim 27 , further comprising determining a first number of EEG sensors contributing to seizure from the plurality of EEG sensors based on the first significance for each of the plurality of EEG sensors and a second number of EEG sensors contributing to seizure from the plurality of EEG sensors based on the second significance for each of the plurality of EEG sensors.

29. The method of claim 28 , further comprising evaluating an efficacy of treatment by comparing the first number of EEG sensors contributing to seizure in the first EEG synchronization to the second number of EEG sensors contributing to seizure in the second EEG synchronization.

30. The method of claim 24 , further comprising modifying the therapy based on at least one of the second EEG synchronization or a comparison of the first and second EEG synchronization.

31. The method of claim 24 , further comprising providing a visual representation of at least one of the first EEG synchronization, the second EEG synchronization, or a comparison of the first and second EEG synchronization to at least one of the patient or a physician.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: ACF FINCO I LP
To: LIVANOVA USA, INC.
Reel/Frame 057552/0378 →
SECURITY INTEREST Recorded Aug 16, 2021
From: LIVANOVA USA, INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 057188/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 16, 2021
From: ARES CAPITAL CORPORATION, AS AGENT FOR THE LENDERS
To: LIVANOVA USA, INC.
Reel/Frame 057189/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 30, 2020
From: LIVANOVA USA, INC.
To: ACF FINCO I LP, AS COLLATERAL AGENT
Reel/Frame 054881/0784 →
PATENT SECURITY AGREEMENT Recorded Jun 17, 2020
From: LIVANOVA USA, INC.
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 053673/0675 →
CHANGE OF NAME Recorded Jun 3, 2019
From: CYBERONICS, INC.
To: LIVANOVA USA, INC.
Reel/Frame 049345/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: SABESAN, SHIVKUMAR
To: CYBERONICS, INC.
Reel/Frame 039565/0961 →